Skip to content

TAK

Takeda Pharmaceutical Company Limited

Key figures

MetricLatest5-year CAGR
Revenue¥4.51TFY2026+7.1%
Gross profit¥2.93TFY2026+5.9%
Operating income¥6.2BFY2026−58.6%
Net income−¥152.4BFY2026—
EPS−¥96.75FY2026—
Free cash flow¥865.4BFY2026−0.8%